Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine
2. Ad 5423
3. Ad-5423
4. Ad5423
5. Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-
6. Lonasen
1. 132810-10-7
2. Lonasen
3. Ad-5423
4. Blonanserin [inn]
5. Ad 5423
6. 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
7. Blonanserin (lonasen)
8. 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine
9. Aq316b4f8c
10. Chembl178803
11. 132810-10-7 (free Base)
12. 2-(4-ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine
13. Ncgc00183858-01
14. 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
15. Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-
16. 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine.
17. Blonanserin (jan/inn)
18. Unii-aq316b4f8c
19. 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine
20. Cycloocta[b]pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-
21. Ad5423
22. Blonanserin [mi]
23. Blonanserin [jan]
24. Blonanserin(ad-5423)
25. Blonanserin [mart.]
26. Dsstox_cid_28716
27. Dsstox_rid_82985
28. Dsstox_gsid_48790
29. Blonanserin [who-dd]
30. Schembl119669
31. Gtpl7670
32. Dtxsid7048790
33. Blonanserin, >=98% (hplc)
34. Chebi:31296
35. Amy8830
36. Ex-a663
37. Hms3740e13
38. Zinc597434
39. Bcp04236
40. Dsp-5423
41. Tox21_113267
42. Bdbm50160807
43. Mfcd00893838
44. Pdsp1_000720
45. Pdsp2_000710
46. S2112
47. Akos005145823
48. Ac-1599
49. Db09223
50. Sb17396
51. Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(1-fluorophenyl)-5,6,7,8,9,10-hexahydro-
52. As-11421
53. Hy-13575
54. A8384
55. B4565
56. Cas-132810-10-7
57. Ft-0663415
58. Ad-5423;ad5423;ad 5423
59. D01176
60. Ab01565798_02
61. 810b107
62. L001392
63. Sr-01000945256
64. Q4927426
65. Sr-01000945256-1
66. 4-(4-fluoro-phenyl)-2-(4-propyl-piperazin-1-yl)-5,6,7,8,9,10-hexahydro-cycloocta[b]pyridine
Molecular Weight | 367.5 g/mol |
---|---|
Molecular Formula | C23H30FN3 |
XLogP3 | 5.5 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 3 |
Exact Mass | 367.24237613 g/mol |
Monoisotopic Mass | 367.24237613 g/mol |
Topological Polar Surface Area | 19.4 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 443 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Used for the treatment of schizophrenia.
Blonanserin antagonizes dopamine and serotonin receptors to reduce symptoms of schizophrenia.
Absorption
Blonanserin has a Tmax of 1.5 h and a bioavailablity of 55%. Tmax has been observed to be prolonged and relative bioavailability increased when administered with food.
Route of Elimination
57% of blonanserin is excreted in the urine and 30% in the feces. Only 5% of the drug in the feces is the parent drug with no parent drug excreted through the urine.
Volume of Distribution
Blonanserin has a Vc of 9500 L and a Vt of 8560 L for a total Vd of 18060 L.
Clearance
Blonanserin has a clearance of 1230 L/h.
Blonanserin is mainly metabolized by CYP3A4. It undergoes hydoxylation of the cyclooctane ring as well as N-oxidation and N-deethylation of the piperazine ring. The N-deethylated and hydroxylated metabolites are active but to a lesser degree than the parent drug.
Blonanserin has a half life of elimination of 10.7-16.2 h.
Blonanserin binds to and inhibits dopamine receptors D2 and D3 as well as the serotonin receptor 5-HT2A with high affinity. Blonanserin has low affinity for other dopamine and serotonin receptors as well as muscarinic, adrenergic, and histamine receptors. This reduces dopaminergic and serotonergic neurotransmission which is thought to produce a reduction in positive and negative symptoms of schizophrenia respectively.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
ABOUT THIS PAGE
A Blonanserin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Blonanserin, including repackagers and relabelers. The FDA regulates Blonanserin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Blonanserin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Blonanserin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Blonanserin supplier is an individual or a company that provides Blonanserin active pharmaceutical ingredient (API) or Blonanserin finished formulations upon request. The Blonanserin suppliers may include Blonanserin API manufacturers, exporters, distributors and traders.
click here to find a list of Blonanserin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Blonanserin Drug Master File in Japan (Blonanserin JDMF) empowers Blonanserin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Blonanserin JDMF during the approval evaluation for pharmaceutical products. At the time of Blonanserin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Blonanserin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Blonanserin Drug Master File in Korea (Blonanserin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Blonanserin. The MFDS reviews the Blonanserin KDMF as part of the drug registration process and uses the information provided in the Blonanserin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Blonanserin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Blonanserin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Blonanserin suppliers with KDMF on PharmaCompass.
A Blonanserin written confirmation (Blonanserin WC) is an official document issued by a regulatory agency to a Blonanserin manufacturer, verifying that the manufacturing facility of a Blonanserin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Blonanserin APIs or Blonanserin finished pharmaceutical products to another nation, regulatory agencies frequently require a Blonanserin WC (written confirmation) as part of the regulatory process.
click here to find a list of Blonanserin suppliers with Written Confirmation (WC) on PharmaCompass.
Blonanserin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Blonanserin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Blonanserin GMP manufacturer or Blonanserin GMP API supplier for your needs.
A Blonanserin CoA (Certificate of Analysis) is a formal document that attests to Blonanserin's compliance with Blonanserin specifications and serves as a tool for batch-level quality control.
Blonanserin CoA mostly includes findings from lab analyses of a specific batch. For each Blonanserin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Blonanserin may be tested according to a variety of international standards, such as European Pharmacopoeia (Blonanserin EP), Blonanserin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Blonanserin USP).
LOOKING FOR A SUPPLIER?